About this Research Topic
The objective of this Research Topic is to summarize the pre-clinical, translational, and clinical data supporting the use of novel therapies for rare cancers from tumor microenvironment of each entity, translational research of drugs a in the drug development pipeline and/or delineating subgroups of tumors or identifying novel biomarkers of response to therapeutic strategies with a strong biological rationale. In particular the rationale for the use of immunotherapies in rare cancers will be discussed. This Research Topic welcomes the following subtopics:
Rare Cancers:
- Sarcomas
- Neuro-oncology
- Head and Neck Tumors
- Mesothelioma
- Thymic Tumors
- Rare gynecologic and breast tumors
- Peritoneal Malignancies
- Anal Cancers
- Hematologic malignancies
Immune Therapies:
- Novel Immune checkpoint blockers
- Combination therapies with standard-of-care treatments such as chemotherapy, radiation therapy or tyrosine kinase inhibitors
- Intra-tumoral treatment
- Novel Cytokines
- Modified T-cell or NK-cell therapies and CAR-T cells/ CAR-NK cells
Note that Topic Editor Dr. Takahiro Tsujikawa is a paid consultant for Merck Biopharma and Rakuten Medical and receives speaker fees from Bristol-Myers Squibb, Merck Biopharma, Eisai Co., Ltd., Merck Sharp & Dohme Corp, Ono Pharmaceutical, Otsuka Pharmaceutical Factory, and Rakuten Medical. Additionally, manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Keywords: Rare Cancers, Immunotherapy, Early Drug Development, Immune Checkpoint Blockers, Sarcoma, Biomarkers
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.